Premium
Bleeding Risk in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Systematic Review and Meta‐Analysis
Author(s) -
Lopes L C,
Spencer F A,
Neumann I,
Ventresca M,
Ebrahim S,
Zhou Q,
Bhatnaga N,
Schulman S,
Eikelboom J,
Guyatt G
Publication year - 2013
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2013.99
Subject(s) - medicine , atrial fibrillation , meta analysis , vitamin k , confidence interval , major bleeding , stroke (engine) , cardiology , mechanical engineering , engineering
Vitamin K antagonists (VKAs) prevent stroke in atrial fibrillation (AF) at the cost of bleeding risk. To determine major bleeding rates in AF patients, we conducted a systematic review that identified 51 eligible studies including more than 342,699 patients. The pooled estimate of the rate of major bleeding was 2.51 (99% confidence interval: 2.03–3.11) bleeds per 100 patient‐years. The results represent the best estimates of bleeding risk that most patients contemplating VKA use may expect. Clinical Pharmacology & Therapeutics (2013); 94 3, 367–375. doi: 10.1038/clpt.2013.99